Citius Oncology, Inc. Increase (Decrease) in Prepaid Expense
Citius Oncology, Inc. (CTOR) reported Increase (Decrease) in Prepaid Expense of $1.50 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-08-14
- Citius Oncology, Inc. increase (decrease) in prepaid expense for the quarter ending 2026-06-30 was -$221.11K.
- Citius Oncology, Inc. increase (decrease) in prepaid expense for the quarter ending 2026-03-31 was -$110.55K.
- Citius Oncology, Inc. increase (decrease) in prepaid expense for the quarter ending 2025-12-31 was $1.83M.
- Citius Oncology, Inc. increase (decrease) in prepaid expense for the quarter ending 2024-09-30 was -$1.17M.
- Citius Oncology, Inc. increase (decrease) in prepaid expense for fiscal 2024 was $1.10M.
- Citius Oncology, Inc. increase (decrease) in prepaid expense for fiscal 2023 was -$62.72K.
- Citius Oncology, Inc. increase (decrease) in prepaid expense for fiscal 2023 was $5.04M.
- Citius Oncology, Inc. increase (decrease) in prepaid expense for fiscal 2022 was $88.17K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$221.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | -$331.66K derived: sum of 2 quarters · filed 2026-08-14 | $1.50M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$110.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $1.72M 10-Q · filed 2026-05-15 | ||
| 2025-12-31 | $1.83M 10-Q · filed 2026-02-13 | |||
| 2025-06-30 | -$1.60M 10-Q · filed 2026-08-14 | |||
| 2024-09-30 | -$1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | -$1.19M derived: sum of 2 quarters · filed 2025-12-23 | -$1.16M derived: sum of 3 quarters · filed 2025-12-23 | $1.10M 10-K · filed 2025-12-23 |
| 2024-06-30 | -$20.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $15.27K 10-Q · filed 2024-08-09 | $2.27M 10-Q · filed 2025-08-12 | -$51.09K derived: sum of 4 quarters · filed 2024-08-09 |
| 2024-03-31 | $35.61K 10-Q · filed 2024-05-20 | $1.17M 10-Q · filed 2025-05-14 | -$30.75K derived: sum of 3 quarters · filed 2024-05-20 | -$63.93K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-12-31 | -$33.18K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$66.36K derived: sum of 2 quarters · filed 2024-04-16 | -$99.54K derived: sum of 3 quarters · filed 2024-08-09 | -$62.72K 10-K · filed 2024-04-16 |
| 2023-09-30 | -$33.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-20 | -$66.36K derived: sum of 2 quarters · filed 2024-08-09 | -$29.54K 10-Q · filed 2023-11-20 | $5.04M 10-K · filed 2024-12-27 |
| 2023-06-30 | -$33.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $3.64K 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $36.82K 10-Q · filed 2024-05-20 | |||
| 2022-12-31 | $88.17K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |